16:36:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-04 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017


ListaOB Match
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss.
2021-11-01 13:07:25
Moss, 1 November 2021

Gentian Diagnostics ASA is pleased to announce that the results from a study
conducted in collaboration with Charité - Universitätsmedizin Berlin and Labor
Berlin have been presented as a poster at the European Society for Emergency
Medicine (EUSEM) congress in Lisbon.

The results are part of an ongoing prospective clinical trial (CASCADE) which is
performed in the Emergency department of the Charité - Universitätsmedizin
Berlin Campus Benjamin Franklin.

The study concluded that the calprotectin levels in plasma were significantly
higher in ventilated than in non-ventilated COVID-19 patients. Moreover,
calprotectin was able to predict need for Intensive Care Unit (ICU) admission
with outstanding performance and an AUROC of 1.0. The performance of
calprotectin in prediction of ICU admission was better than performance of the
biomarker procalcitonin.

10 COVID-19 patients with positive SARS-CoV-2 PCR test were enrolled and the
value of calprotectin in prediction of need for admission to ICU and the need
for mechanical ventilation was also investigated.

The conclusion from this study supports calprotectin as an early biomarker for
risk stratification and optimal management of COVID-19 patients. Early
identification of patients with severe form of the disease is of critical
importance for optimal patient care and use of healthcare resources. The authors
also confirm that use of Gentian's calprotectin assay GCAL® supports an easily
accessible and efficient measurement of calprotectin in routine laboratories.

For further information please see the enclosed poster.
IR contact:

Njaal Kind, CFO and COO
+47 919 06 525 (mobile)

About Gentian
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.